{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:45Z","timestamp":1791264525318,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1053\/j.seminoncol.2007.10.006","type":"journal-article","created":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T03:11:54Z","timestamp":1208229114000},"page":"S17-S23","source":"Crossref","is-referenced-by-count":35,"special_numbering":"S4","title":["Clinical Benefits and Considerations of Bisphosphonate Treatment in Metastatic Bone Disease"],"prefix":"10.1053","volume":"34","author":[{"given":"Fred","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2007.10.006_bib1","first-page":"18","article-title":"Cancer and bone","volume":"19","author":"Guise","year":"1998","journal-title":"Endocr Rev"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib2","first-page":"205","article-title":"Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention","volume":"2","author":"Lipton","year":"2004","journal-title":"J Support Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib3","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib4","first-page":"377","article-title":"Assessment and treatment of patients with malignant spinal cord compression","volume":"2","author":"Abrahm","year":"2004","journal-title":"J Support Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib5","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2005.00.067","article-title":"Systematic review of the diagnosis and management of malignant extradural spinal cord compression: The Cancer Care Ontario Practice Guidelines Initiative\u2019s Neuro-Oncology Disease Site Group","volume":"23","author":"Loblaw","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib6","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib7","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1614::AID-CNCR12>3.0.CO;2-2","article-title":"Orthopedic surgical management of skeletal complications of malignancy","volume":"80","author":"Harrington","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2007.10.006_bib9","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ejon.2007.07.002","article-title":"Burden of bone disease","volume":"11","author":"Kinnane","year":"2007","journal-title":"Eur J Oncol Nurs"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib12","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib13","series-title":"Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone [poster]","author":"Saad","year":"2003"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib16","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1002\/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.0.CO;2-C","article-title":"Bisphosphonates and breast carcinoma: present and future","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib17","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2007.10.006_bib18","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00000421-200212001-00003","article-title":"Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints","volume":"25","author":"Major","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib19","series-title":"Fractures negatively affect survival in patients with bone metastases from breast cancer [poster]","author":"Hei","year":"2005"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib21","series-title":"Fractures negatively impact survival in patients with multiple myeloma or bone metastases from solid tumors [poster]","author":"Saad","year":"2005"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib22","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib23","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J Intern Med"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2007.10.006_bib25","first-page":"761","article-title":"Multiple event analysis of skeletal complications: zoledronic acid in phase III trials","volume":"22","author":"Belch","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib26","series-title":"Efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma","author":"Lipton","year":"2004"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib27","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib30","first-page":"701","article-title":"[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bull Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib31","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Schmidt RL, Stockler M: Bisphosphonates for breast cancer (review). The Cochrane Database Systematic Review 2005, Issue 3. Art. no.: CD003474.pub2. DOI: 10.1002\/14651858.CD003474.pub2","DOI":"10.1002\/14651858.CD003474.pub2"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib32","series-title":"Zoledronic acid has broad long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer, prostate cancer, and other solid tumors","author":"Coleman","year":"2004"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2007.10.006_bib33","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.ejon.2007.07.003","article-title":"Optimal management of metastatic bone disease","volume":"11","author":"Major","year":"2007","journal-title":"Eur J Oncol Nurs"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib34","series-title":"Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases [poster]","author":"Zheng","year":"2005"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib35","series-title":"Long-term reduction of bone pain and skeletal morbidity with zoledronic acid in patients with prostate cancer and bone metastases [poster]","author":"Saad","year":"2005"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib36","series-title":"Breast cancer patients without pain are at risk for skeletal-related events (SREs) and may have better outcomes with zoledronic acid compared with pamidronate [poster]","author":"Costa","year":"2006"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib37","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib38","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib40","series-title":"Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone [poster]","author":"Saad","year":"2003"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib41","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/ctrv.2000.0212","article-title":"Bone markers in the management of metastatic bone disease","volume":"27","author":"Lipton","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib44","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","article-title":"Markers of bone resorption in patients treated with pamidronate","volume":"34","author":"Lipton","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib45","first-page":"1457","article-title":"Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid","volume":"25","author":"Pectasides","year":"2005","journal-title":"Anticancer Res"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2007.10.006_bib46","first-page":"496s","article-title":"Normalization of bone markers and improved survival during zoledronic acid therapy","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.3589.3589","article-title":"Zoledronic acid may improve survival compared to pamidronate in patients with MM and High BALP levels: univariate and multivariate models of hazard ratios","volume":"108","author":"Berenson","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib48","doi-asserted-by":"crossref","first-page":"421s","DOI":"10.1200\/jco.2006.24.18_suppl.7228","article-title":"Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: Stratified by baseline bone alkaline phosphatase (BALP)","volume":"24","author":"Matczak","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib49","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.006_bib50","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T09:07:56Z","timestamp":1588583276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775407002084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":50,"alternative-id":["S0093775407002084"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2007.10.006","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}